雌激素
雌酮
芳香化酶
背景(考古学)
芳构化
转录因子
免疫系统
动物研究
临床试验
电池类型
医学
内分泌学
癌症研究
促炎细胞因子
间充质干细胞
内科学
雌激素受体
细胞
生物
化学
炎症
抄写(语言学)
生物信息学
增强子
人体研究
药理学
肿瘤转化
羟基化
生物活性
基础研究
基因
作者
Richard J. Santen,Anne Gompel,Karen O Klein,Mary Ann Lumsden,JoAnn V Pinkerton,Cynthia A. Stuenkel,Wei Yue
标识
DOI:10.1210/clinem/dgag213
摘要
CONTEXT: Recent studies challenge the traditional view that estrone (E1) must be converted to estradiol (E2) to be biologically active. The prior view was based on several findings: E2 binds to ERα and ERβ, and their nuclear coactivators, with 4 to 25 times greater affinity than E1. 17β-hydroxysteroid dehydrogenases can efficiently convert E1 to E2 in vivo. Observations from cell culture, animal models, and clinical studies have supported the idea that E1's biological effects depend on its conversion to E2. EVIDENCE ACQUISITION: A systematic search was conducted using PubMed, Ovid Medline, Embase, Web of Science and bibliographies of manuscripts to obtain pertinent data. EVIDENCE SYNTHESIS: In postmenopausal women, plasma levels of E1 are 4-fold higher than those of E2, and the E1 production through peripheral aromatization is 8-fold higher. Recent research has shown that E1 has distinct effects on brain function, gene expression, breast tissue inflammation, immune modulation, epithelial to mesenchymal cell transformation (EMT), stem cells, and vascular endothelial cells. The specific recruitment of coactivators to enhancer complexes during nuclear transcription may explain these unique actions of E1. Collectively, these findings provide evidence that E1 can act independently of conversion to E2. Extensive study is now required regarding clinical implications for the selection of type of estrogen therapy after menopause, especially regarding cognitive function, mood disorders, and effects on breast inflammation '. CONCLUSION: Current evidence indicates that E1 is a biologically significant estrogen in its own right. Further preclinical and clinical studies are needed to clarify E1's unique effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI